查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1636791

2030 年丙型肝炎药物市场预测：按产品、治疗类型、药物类别、给药途径、疾病阶段、最终用户和地区进行的全球分析

Hepatitis C Drugs Market Forecasts to 2030 - Global Analysis By Product (Generic Hepatitis C Drugs and Branded Hepatitis C Drugs), Treatment Type, Drug Class, Route Of Administration, Disease Stage, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球丙型肝炎药物市场预计在 2024 年达到 259.2 亿美元，到 2030 年将达到 365.7 亿美元，预测期内的复合年增长率为 6.2%。

丙型肝炎药物是用于治疗C型肝炎（一种影响肝臟的病毒感染疾病）的药物。这些药物透过在C型肝炎病毒(HCV) 生命週期的不同阶段发挥作用，要么阻止病毒复製，要么增强免疫系统抵抗病毒的能力。这些药物通常合併使用，以显着提高治癒率，缩短治疗时间，并最大限度地减少副作用。

根据美国疾病管制与预防美国（CDC）2016年的数据，美国约有350万人患有慢性C型肝炎。

丙型肝炎盛行率不断上升

随着越来越多的人被诊断出患有丙型肝炎，对先进治疗方案的需求也日益增长，尤其是直接抗病毒药物 (DAA)，这些药物以高效和副作用小而闻名。公共卫生措施和宣传宣传活动进一步加强了筛检和早期检测工作，从而增加了寻求治疗的患者数量。此外，医疗保健提供者和政府致力于消除丙型肝炎，对研究、津贴和伙伴关係关係的投资有助于扩大市场并改善获得丙型肝炎药物的机会。

副作用和抗药性

丙型肝炎药物的副作用和抗药性是由患者反应的多变性和病毒的变异能力所造成的。一些治疗方法，尤其是像干扰素治疗方法这样的老疗法，会引起严重的副作用，如疲劳、忧郁和类流感症状，从而降低患者的依从性。这些因素限制了治疗的有效性，增加了对替代疗法的需求，降低了患者信心，并最终减缓了采用和治疗完成率，从而阻碍了市场成长。

扩大医疗基础设施和保险覆盖范围

卫生基础设施的改善将提高人们获得诊断和治疗设施的机会，从而能够早期发现丙型肝炎并及时干预。扩大保险覆盖范围将减轻患者的经济负担，使得 DAA 等昂贵的治疗更加实惠。政府措施和私营部门对医疗保健系统的投资（尤其是在新兴经济体中）确保了先进治疗的可用性，从而进一步推动了市场成长。这些发展将使更多患者能够接受治疗，增加对有效丙型肝炎药物的需求并改善整体健康。

学名药的竞争

学名药以极低的成本提供类似的功效，吸引了注重价格的患者和医疗保健提供者。这种转变限制了高价品牌药的市场占有率，尤其是在中低收入地区。而学名药的推出往往引发价格战，进一步挤压主要企业的利润空间。具有成本效益的学名药的供应也可能阻碍对开发新药的投资，从而减缓丙型肝炎治疗的创新。

COVID-19 的影响

COVID-19 疫情对C型肝炎药物市场产生了重大影响，扰乱了医疗保健系统、诊断和治疗。由于医疗资源被转移到控制 COVID-19，丙型肝炎的诊断和治疗被推迟。此外，旅行限制和封锁影响了患者获得治疗和药物的机会。但公众健康意识和远端医疗的增强有助于维持一些治疗工作。此次疫情也将重点转移到加强卫生基础设施上，这可能有助于未来疫情后的丙型肝炎管理。

预测期内单一疗法市场规模预计最大

预计单一疗法领域将在整个预测期内占据最大的市场占有率。丙型肝炎单一疗法治疗是指使用单一抗病毒药物治疗感染疾病。单一疗法包括干扰素和Ribavirin，但随着直接抗病毒药物（DAA）的出现，单一疗法变得更有效且耐受性更好。它们通常用于具有特定基因型或症状较轻的患者，以确保疗效同时最大限度地减少副作用。

预测期内，慢性丙型肝炎市场预计将以最高复合年增长率成长

预计预测期内慢性丙型肝炎部分将出现最高的复合年增长率。用于治疗慢性C型肝炎的C型肝炎药物主要用于消除体内的病毒和预防肝损伤。这些药物通常合併使用，具有很高的疗效和治癒率，且副作用小。治疗通常持续8至12週，这些治疗方法有助于减少肝硬化、肝癌和肝功能衰竭等併发症。

比最大的地区

由于人们认识的提高、医疗保健机会的改善以及丙型肝炎患病率的上升，预计亚太地区将在预测期内占据最大的市场占有率。印度、中国和日本等国家因患者人数众多且政府医疗保健措施而主导市场。该地区也是百时美施贵宝、西普拉和雷迪博士实验室等主要企业的所在地。快速的都市化、不断扩大的医疗保健基础设施以及有利的政府政策正在推动该地区的市场成长。

复合年增长率最高的地区：

由于北美拥有先进的医疗保健体系和对研发的大量投资，预计在预测期内北美将实现最高的复合年增长率。该地区的主要企业包括吉利德科学、艾伯维、默克公司和百时美施贵宝。由于政府资助的医疗保健计划、保险覆盖范围的扩大以及丙型肝炎消除努力的加强，该地区的市场正在稳步增长。 DAA 的采用和针对高风险族群的努力改善了治疗的机会和结果，确保北美仍然是全球主导市场。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业进行基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第 5 章 全球丙型肝炎药物市场（按产品）

  • 非专利肝炎药物
  • 品牌丙型肝炎药物

6. 全球丙型肝炎药物市场依治疗类型划分

  • 联合治疗
  • 单药治疗

7. 全球丙型肝炎药物市场（依药物类别）

  • 直接抗病毒药物 (DAA)
  • 蛋白酶抑制剂
  • NS5A 抑制剂
  • NS5B 抑制剂
  • 伴随用药
  • Ribavirin
  • 其他药物类别

8. 全球丙型肝炎药物市场依给药途径划分

  • 口服药物
  • 注射药物

第 9 章 全球C型肝炎药物市场（依疾病阶段）

  • 急性C型肝炎
  • 慢性C型肝炎

第 10 章 全球C型肝炎药物市场（依最终使用者）

  • 医院
  • 诊所
  • 研究和诊断实验室
  • 其他最终用户

第 11 章 全球丙型肝炎药物市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司概况

  • Gilead Sciences
  • AbbVie
  • Merck & Co.
  • Johnson & Johnson
  • Bristol-Myers Squibb
  • Roche
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Novartis
  • Sanofi
  • Pfizer
  • Boehringer Ingelheim
  • Mylan Pharmaceuticals
  • Teva Pharmaceuticals
  • Cipla
  • Hetero Drugs
  • NephroPlus
  • Aurobindo Pharma
  • Dr. Reddy's Laboratories
  • Zydus Cadila
Product Code: SMRC28433

According to Stratistics MRC, the Global Hepatitis C Drugs Market is accounted for $25.92 billion in 2024 and is expected to reach $36.57 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Hepatitis C drugs are medications used to treat Hepatitis C, a viral infection that affects the liver. These drugs work by targeting the Hepatitis C virus (HCV) at various stages of its lifecycle, such as preventing viral replication or boosting the immune system's ability to fight the virus. These drugs are often used in combination, have significantly improved cure rates, reduced treatment durations, and minimized side effects.

According to the Centers for Disease Control and Prevention (CDC) in 2016, an estimated 3.5 million people in the United States suffered from chronic hepatitis C.

Market Dynamics:

Driver:

Increasing prevalence of hepatitis C

As more people are diagnosed with the infection, there is a growing need for advanced treatment options, particularly Direct-Acting Antivirals (DAAs), known for their high efficacy and minimal side effects. Public health initiatives and awareness campaigns further amplify screening and early detection efforts, creating a larger patient pool seeking treatment. Additionally, healthcare providers and governments focus on eradicating the disease, leading to investments in research, subsidies, and partnerships, which support market expansion and improved accessibility to Hepatitis C drugs.

Restraint:

Side effects and drug resistance

Side effects and drug resistance in Hepatitis C drugs stem from the variability in patient response and the virus's ability to mutate. Some treatments, particularly older regimens like interferon-based therapies, cause significant side effects, such as fatigue, depression, and flu-like symptoms, discouraging patient adherence. These factors hamper market growth by limiting treatment efficacy, increasing the need for alternative therapies, and reducing patient trust, ultimately slowing adoption and treatment completion rates.

Opportunity:

Expanding healthcare infrastructure and insurance coverage

Improved healthcare infrastructure increases access to diagnostic and treatment facilities, enabling earlier detection and timely intervention for Hepatitis C. Enhanced insurance coverage lowers the financial burden on patients, making expensive therapies like DAAs more affordable. Government initiatives and private sector investments in healthcare systems, particularly in emerging economies, further drive market growth by ensuring the availability of advanced treatments. These developments collectively encourage more patients to seek care, boosting demand for effective Hepatitis C drugs and improving overall health outcomes.

Threat:

Competition from generic drugs

Generics offer similar efficacy at a fraction of the cost, attracting price-sensitive patients and healthcare providers. This shift limits the market share of premium-priced branded drugs, especially in low- and middle-income regions. Additionally, the introduction of generics often leads to price wars, further compressing profit margins for companies. The availability of cost-effective generics also discourages investment in new drug development, potentially slowing innovation in the Hepatitis C treatment landscape.

Covid-19 Impact

The covid-19 pandemic significantly impacted the hepatitis C drugs market, disrupting healthcare systems, diagnostics, and treatments. The diversion of healthcare resources to manage covid led to delays in hepatitis C diagnosis and treatment initiation. Additionally, travel restrictions and lockdowns affected patient access to care and medications. However, increased awareness of public health and telemedicine helped sustain some treatment efforts. The pandemic also shifted focus toward enhancing healthcare infrastructure, which may aid in future Hepatitis C management post-covid.

The monotherapy segment is expected to be the largest during the forecast period

The monotherapy segment is predicted to secure the largest market share throughout the forecast period. Monotherapy in Hepatitis C treatment refers to using a single antiviral drug to treat the infection. Monotherapy involves interferon or ribavirin, but with the advent of Direct-Acting Antivirals (DAAs), monotherapy has become more effective and well-tolerated. It is often used for patients with specific genotypes or mild disease, minimizing side effects while ensuring effectiveness.

The chronic hepatitis C segment is expected to have the highest CAGR during the forecast period

The chronic hepatitis C segment is anticipated to witness the highest CAGR during the forecast period. Hepatitis C drugs used in chronic Hepatitis C treatment are primarily focused on eliminating the virus from the body and preventing liver damage. These drugs, often used in combination, are highly effective, offering high cure rates with minimal side effects. Treatment duration typically ranges from 8 to 12 weeks, and these therapies help reduce complications like cirrhosis, liver cancer, and liver failure.

Region with largest share:

Asia Pacific is expected to register the largest market share during the forecast period due to increasing awareness, improved healthcare access, and rising Hepatitis C prevalence. Countries like India, China, and Japan dominate the market, driven by large patient populations and government health initiatives. The region is also home for key players such as Bristol-Myers Squibb, Cipla, and Dr. Reddy's Laboratories. Rapid urbanization, expanding healthcare infrastructure, and favorable government policies are propelling the market's growth in this region.

Region with highest CAGR:

North America is expected to witness the highest CAGR over the forecast period driven by advanced healthcare systems and substantial investments in research and development. Key players in the region include Gilead Sciences, AbbVie Inc., Merck & Co., and Bristol-Myers Squibb. The region experiences steady market growth due to government-supported health programs, insurance coverage, and increasing efforts to eradicate Hepatitis C. The adoption of DAAs, coupled with initiatives targeting high-risk populations, ensures improved treatment access and outcomes, solidifying North America as a dominant market globally.

Key players in the market

Some of the key players profiled in the Hepatitis C Drugs Market include Gilead Sciences, AbbVie, Merck & Co., Johnson & Johnson, Bristol-Myers Squibb, Roche, GlaxoSmithKline, Eli Lilly and Company, Novartis, Sanofi, Pfizer, Boehringer Ingelheim, Mylan Pharmaceuticals, Teva Pharmaceuticals, Cipla, Hetero Drugs, NephroPlus, Aurobindo Pharma, Dr. Reddy's Laboratories and Zydus Cadila.

Key Developments:

In September 2024, NephroPlus has introduced a pioneering program aimed at addressing the critical issue of Hepatitis C in haemodialysis patients, particularly in regions with limited healthcare resources. This initiative highlights NephroPlus' ongoing commitment to enhancing patient care and reinforcing the health system's capabilities.

In April 2022, Bristol-Myers Squibb & Gilead Sciences entered a strategic collaboration to further develop their Hepatitis C drug pipelines. The deal focused on the combined development of new combination therapies for chronic Hepatitis C virus (HCV) infections, leveraging both companies' research assets to expand treatment options and improve cure rates.

Products Covered:

  • Generic Hepatitis C Drugs
  • Branded Hepatitis C Drugs

Treatment Types Covered:

  • Combination Therapy
  • Monotherapy

Drug Classes Covered:

  • Direct-Acting Antivirals (DAAs)
  • Protease Inhibitors
  • NS5A Inhibitors
  • NS5B Inhibitors
  • Combination Drugs
  • Ribavirin
  • Other Drug Classes

Route Of Administrations Covered:

  • Oral Drugs
  • Injectable Drugs

Disease Stages Covered:

  • Acute Hepatitis C
  • Chronic Hepatitis C

End Users Covered:

  • Hospitals
  • Clinics
  • Research & Diagnostic Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hepatitis C Drugs Market, By Product

  • 5.1 Introduction
  • 5.2 Generic Hepatitis C Drugs
  • 5.3 Branded Hepatitis C Drugs

6 Global Hepatitis C Drugs Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Combination Therapy
  • 6.3 Monotherapy

7 Global Hepatitis C Drugs Market, By Drug Class

  • 7.1 Introduction
  • 7.2 Direct-Acting Antivirals (DAAs)
  • 7.3 Protease Inhibitors
  • 7.4 NS5A Inhibitors
  • 7.5 NS5B Inhibitors
  • 7.6 Combination Drugs
  • 7.7 Ribavirin
  • 7.8 Other Drug Classes

8 Global Hepatitis C Drugs Market, By Route Of Administration

  • 8.1 Introduction
  • 8.2 Oral Drugs
  • 8.3 Injectable Drugs

9 Global Hepatitis C Drugs Market, By Disease Stage

  • 9.1 Introduction
  • 9.2 Acute Hepatitis C
  • 9.3 Chronic Hepatitis C

10 Global Hepatitis C Drugs Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Clinics
  • 10.4 Research & Diagnostic Laboratories
  • 10.5 Other End Users

11 Global Hepatitis C Drugs Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Gilead Sciences
  • 13.2 AbbVie
  • 13.3 Merck & Co.
  • 13.4 Johnson & Johnson
  • 13.5 Bristol-Myers Squibb
  • 13.6 Roche
  • 13.7 GlaxoSmithKline
  • 13.8 Eli Lilly and Company
  • 13.9 Novartis
  • 13.10 Sanofi
  • 13.11 Pfizer
  • 13.12 Boehringer Ingelheim
  • 13.13 Mylan Pharmaceuticals
  • 13.14 Teva Pharmaceuticals
  • 13.15 Cipla
  • 13.16 Hetero Drugs
  • 13.17 NephroPlus
  • 13.18 Aurobindo Pharma
  • 13.19 Dr. Reddy's Laboratories
  • 13.20 Zydus Cadila

List of Tables

  • Table 1 Global Hepatitis C Drugs Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Hepatitis C Drugs Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Hepatitis C Drugs Market Outlook, By Generic Hepatitis C Drugs (2022-2030) ($MN)
  • Table 4 Global Hepatitis C Drugs Market Outlook, By Branded Hepatitis C Drugs (2022-2030) ($MN)
  • Table 5 Global Hepatitis C Drugs Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 6 Global Hepatitis C Drugs Market Outlook, By Combination Therapy (2022-2030) ($MN)
  • Table 7 Global Hepatitis C Drugs Market Outlook, By Monotherapy (2022-2030) ($MN)
  • Table 8 Global Hepatitis C Drugs Market Outlook, By Drug Class (2022-2030) ($MN)
  • Table 9 Global Hepatitis C Drugs Market Outlook, By Direct-Acting Antivirals (DAAs) (2022-2030) ($MN)
  • Table 10 Global Hepatitis C Drugs Market Outlook, By Protease Inhibitors (2022-2030) ($MN)
  • Table 11 Global Hepatitis C Drugs Market Outlook, By NS5A Inhibitors (2022-2030) ($MN)
  • Table 12 Global Hepatitis C Drugs Market Outlook, By NS5B Inhibitors (2022-2030) ($MN)
  • Table 13 Global Hepatitis C Drugs Market Outlook, By Combination Drugs (2022-2030) ($MN)
  • Table 14 Global Hepatitis C Drugs Market Outlook, By Ribavirin (2022-2030) ($MN)
  • Table 15 Global Hepatitis C Drugs Market Outlook, By Other Drug Classes (2022-2030) ($MN)
  • Table 16 Global Hepatitis C Drugs Market Outlook, By Route Of Administration (2022-2030) ($MN)
  • Table 17 Global Hepatitis C Drugs Market Outlook, By Oral Drugs (2022-2030) ($MN)
  • Table 18 Global Hepatitis C Drugs Market Outlook, By Injectable Drugs (2022-2030) ($MN)
  • Table 19 Global Hepatitis C Drugs Market Outlook, By Disease Stage (2022-2030) ($MN)
  • Table 20 Global Hepatitis C Drugs Market Outlook, By Acute Hepatitis C (2022-2030) ($MN)
  • Table 21 Global Hepatitis C Drugs Market Outlook, By Chronic Hepatitis C (2022-2030) ($MN)
  • Table 22 Global Hepatitis C Drugs Market Outlook, By End User (2022-2030) ($MN)
  • Table 23 Global Hepatitis C Drugs Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 24 Global Hepatitis C Drugs Market Outlook, By Clinics (2022-2030) ($MN)
  • Table 25 Global Hepatitis C Drugs Market Outlook, By Research & Diagnostic Laboratories (2022-2030) ($MN)
  • Table 26 Global Hepatitis C Drugs Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.